These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23202926)

  • 1. Fragment-based screening by protein crystallography: successes and pitfalls.
    Chilingaryan Z; Yin Z; Oakley AJ
    Int J Mol Sci; 2012 Oct; 13(10):12857-79. PubMed ID: 23202926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences in fragment-based drug discovery.
    Murray CW; Verdonk ML; Rees DC
    Trends Pharmacol Sci; 2012 May; 33(5):224-32. PubMed ID: 22459076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multiple roles of computational chemistry in fragment-based drug design.
    Law R; Barker O; Barker JJ; Hesterkamp T; Godemann R; Andersen O; Fryatt T; Courtney S; Hallett D; Whittaker M
    J Comput Aided Mol Des; 2009 Aug; 23(8):459-73. PubMed ID: 19533374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of fragment screening by X-ray crystallography to beta-secretase.
    Murray CW; Callaghan O; Chessari G; Cleasby A; Congreve M; Frederickson M; Hartshorn MJ; McMenamin R; Patel S; Wallis N
    J Med Chem; 2007 Mar; 50(6):1116-23. PubMed ID: 17315856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast fragment- and compound-screening pipeline at the Swiss Light Source.
    Kaminski JW; Vera L; Stegmann DP; Vering J; Eris D; Smith KML; Huang CY; Meier N; Steuber J; Wang M; Fritz G; Wojdyla JA; Sharpe ME
    Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):328-336. PubMed ID: 35234147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
    Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
    Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging structural approaches: applications of NMR-based screening and X-ray crystallography for inhibitor design.
    Moore J; Abdul-Manan N; Fejzo J; Jacobs M; Lepre C; Peng J; Xie X
    J Synchrotron Radiat; 2004 Jan; 11(Pt 1):97-100. PubMed ID: 14646145
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    de Souza Neto LR; Moreira-Filho JT; Neves BJ; Maidana RLBR; Guimarães ACR; Furnham N; Andrade CH; Silva FP
    Front Chem; 2020; 8():93. PubMed ID: 32133344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.
    Congreve M; Aharony D; Albert J; Callaghan O; Campbell J; Carr RA; Chessari G; Cowan S; Edwards PD; Frederickson M; McMenamin R; Murray CW; Patel S; Wallis N
    J Med Chem; 2007 Mar; 50(6):1124-32. PubMed ID: 17315857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein crystallography and fragment-based drug design.
    Caliandro R; Belviso DB; Aresta BM; de Candia M; Altomare CD
    Future Med Chem; 2013 Jun; 5(10):1121-40. PubMed ID: 23795969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment approaches in structure-based drug discovery.
    Hubbard RE
    J Synchrotron Radiat; 2008 May; 15(Pt 3):227-30. PubMed ID: 18421145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fragment-based screening by X-ray structure analysis].
    Yamano A
    Yakugaku Zasshi; 2010 Mar; 130(3):335-40. PubMed ID: 20190518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural biology and drug discovery.
    Scapin G
    Curr Pharm Des; 2006; 12(17):2087-97. PubMed ID: 16796557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.